Desentum’s lead product candidate is DM-101PX, a modified birch pollen hypoallergen formulated for subcutaneous injection with controlled release and reduced allergenicity. DM-101PX is being evaluated in a clinical study in Canada that tests safety and tolerability of 10 weekly doses and assesses effects on allergic symptoms using controlled birch pollen exposure, with preliminary results described as promising. The company aims to reduce the number of required injections for birch pollen treatment while maintaining effectiveness. Desentum is also developing preclinical hypoallergen candidates targeting peanut and grass pollen allergies and plans to apply the same design approach across other allergens. The firm is a spin-off from VTT Technical Research Centre of Finland Ltd and was founded in 2011. It has previously received a Horizon 2020 SME instrument grant and earlier funding from Springvest. Desentum develops novel immunotherapeutic hypoallergens—biotechnologically produced, modified allergen proteins—aimed at improving the efficacy of allergen immunotherapy and shortening treatment time. Its lead candidate, birch pollen hypoallergen DM-101, has completed a First-in-Human clinical study and was found to be safe and well tolerated at the highest tested dosing regimens. Immunological marker results from that study indicated a favorable change in markers associated with a protective response. The company intends to use the newly raised funds to support further clinical development, R&D of new hypoallergens, and business development. Desentum recently raised €8M in funding to advance these programs. The company is led by CEO Pekka Mattila and was founded in 2011 as a spin-off from VTT Technical Research Centre of Finland Ltd.

Total raised

$22M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2024